Crow's Feet Lines Clinical Trial
Verified date | April 2019 |
Source | Allergan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).
Status | Completed |
Enrollment | 446 |
Est. completion date | July 1, 2011 |
Est. primary completion date | April 1, 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Moderate to severe Crow's Feet Lines - Have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses OK) Exclusion Criteria: - Current or previous botulinum toxin treatment of any serotype - Facial laser or light treatment, microdermabrasion or superficial peels within 3 months - Oral retinoid therapy within 1 year - Prior facial cosmetic surgery (eg, periorbital surgery, facial lift, brow lift, eye lift, or eyebrow surgery) - Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Allergan |
United States, Belgium, Canada, United Kingdom,
Carruthers A, Bruce S, de Coninck A, Connolly S, Cox SE, Davis PG, Campo A, Lei X, Somogyi C, Lee E, McLean H, Beddingfield F. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial. Dermatol Surg. 2014 Nov;40(11):1181-90. doi: 10.1097/DSS.0000000000000128. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile | The composite facial wrinkle scale assessment is based on both the Investigator and Subject Facial Wrinkle scales at Day 30. The Investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe and the patient assessed the severity of their Crow's Feet Lines at maximum smile using the same 4-point Facial Wrinkle Scale. A responder is defined as a participant with a = 2-grade improvement from Baseline. | Baseline, Day 30 | |
Secondary | Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator's Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines | The Investigator assessed the severity of the patient's Crow's Feet lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported. | Day 30 | |
Secondary | Percentage of Participants With a = 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Maximum Smile | The Investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a = 1-grade improvement from Baseline at Day 30 is reported. | Baseline, Day 30 | |
Secondary | Percentage of Participants With a = 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Rest | The Investigator assessed the severity of the patient's Crow's Feet Lines at rest using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a = 1-grade improvement from Baseline at Day 30 is reported. | Baseline, Day 30 | |
Secondary | Subject Global Assessment of Change in Crow's Feet Lines (SGA-CFL) Score | Patients rated the change in their Crow's Feet Lines using the SGA-CFL 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse or 7=very much worse at Day 30. Lower scores indicate improvement. | Day 30 | |
Secondary | Percentage of Participants Who Judged Themselves in a Younger Self-Perception of Age Category Than at Baseline | Participants were considered to judge themselves younger if the category change was from "look my current age" at Baseline to "look younger" at Day 30 or from "look older" at Baseline to "look my current age/younger" at Day 30. | Baseline, Day 30 | |
Secondary | Percentage of Participants With a = 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 2 at Day 30 | The percentage of FLO-11 Item #2 responders, defined as participants with a = 2-point improvement in FLO-11 score from Baseline for FLO-11 Question #2: "When I look in the mirror, my facial lines make me look older than I want to look." The FLO-11 questionnaire is comprised of 11 items that assess the subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on an 11-point scale (0=not at all, 5=somewhat, 10=very much). | Baseline, Day 30 | |
Secondary | Percentage of Participants With a = 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 5 at Day 30 | The percentage of FLO-11 Item #5 responders, defined as participants with a = 2-point improvement in FLO-11 score from Baseline for FLO-11 Question #5: "My facial lines make me look less attractive than I want to look." The FLO-11 questionnaire is comprised of 11 items that assess the subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on an 11-point scale (0=not at all, 5=somewhat, 10=very much). | Baseline, Day 30 | |
Secondary | Percentage of Participants With a = 3-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 8 at Day 30 | The percentage of FLO-11 Item #8 responders, defined as participants with a = 3-point improvement in FLO-11 score from baseline for FLO-11 Question #8: "My facial lines make me look tired" The FLO-11 questionnaire is comprised of 11 items that assess the subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on an 11-point scale (0=not at all, 5=somewhat, 10=very much). | Baseline, Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02248844 -
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
|
||
Completed |
NCT02195687 -
BOTOX® in the Treatment of Crow's Feet Lines in China
|
Phase 3 | |
Completed |
NCT01189760 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
Recruiting |
NCT04081402 -
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
|
Phase 3 | |
Completed |
NCT01224015 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
Completed |
NCT02176356 -
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
|
Phase 4 | |
Not yet recruiting |
NCT06402058 -
A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement
|
N/A | |
Completed |
NCT06376838 -
To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet
|
N/A | |
Not yet recruiting |
NCT03184363 -
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
|
Phase 3 | |
Completed |
NCT01797081 -
BOTOX® in the Treatment of Crow's Feet Lines in Japan
|
Phase 3 | |
Completed |
NCT03408236 -
Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
|
Phase 3 | |
Completed |
NCT01797094 -
BOTOX® in the Treatment of Upper Facial Lines in Japan
|
Phase 3 | |
Completed |
NCT03317574 -
MEDITOXIN® in Treatment of Crow's Feet Line
|
Phase 3 |